An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.

Key facts

Study ID

NCT01418677

Run by

Eisai Inc.

People needed

19

Starts

2011-10-01

Expected to finish

2015-05-01

Last updated by the study team

2016-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy).
• Renal function must fall into one of the following categories:
• Normal function - creatinine clearance greater than or equal to 80 mL/min.
• Moderate impairment - creatinine clearance >30 to 50 mL/min.
• Severe impairment - creatinine clearance 15 to less than 30 mL/min.
• Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times the ULN (in the case of liver metastasis less than or equal to 5 times ULN). In the case ALP >3 times the ULN (in the absence of liver metastasis) or >5 times the ULN (in the presence of liver metastasis), and the subject is also known to have bone metastasis, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.

You may not qualify if…

• Subjects with mild renal impairment (creatinine clearance greater than 50 to less than 80 mL/min).
• Subjects with end stage renal disease (creatinine clearance less than 15 mL/min or on dialysis).
• Subjects with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivatives.
• Subjects with prior participation in an HALAVEN clinical study, even if not previously assigned to HALAVEN treatment.
• Radiation therapy encompassing >30 % of bone marrow.
• Subjects with organ allografts requiring immunosuppression.

Where it is running

• Study site — Duarte, California, United States
• Study site — Miami, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Detroit, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — New Brunswick, New Jersey, United States
• Study site — The Bronx, New York, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.